Toxicity Assessment of Precision-Engineered Allo-HSCT

EP: 1.Role of Allogeneic Transplants in Hematologic Malignancies

EP: 2.Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

EP: 3.Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

EP: 4.Transplant Complications and Survival Outcomes

EP: 5.Clinical Trial Update: CTN Trial

EP: 6.Graft-versus-Host Disease Prophylaxis and Management

EP: 7.Patient Case Studies of GvHD

EP: 8.Emerging Cellular Therapies in Hematologic Malignancies

EP: 9.Transplant in the Elderly Population

Now Viewing

EP: 10.Toxicity Assessment of Precision-Engineered Allo-HSCT

EP: 11.The Role of Allo-HSCT in Higher-Risk MDS

EP: 12.Investigational Allo-HSCT for Advanced Hematologic Malignancies

EP: 13.The Future of Allo-HSCT and Cellular Therapies

EP: 14.OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The panel discusses the toxicities observed with the Orca T-cell therapy (Orca-T) graft, a graft manipulation approach that involves adding regulatory T-cells and conventional T-cells (Tcons) to a CD34-selected graft. Due to tacrolimus alone, without methotrexate, patients experience minimal toxicities, faster engraftment, and earlier hospital discharge. The most notable change is the minimal incidence of mucositis, with only 2 patients (1 younger and 1 older) experiencing grade 3 or higher mucositis in the study presented.

The Orca-T platform is currently being evaluated in myeloablative transplants, and the next step is to assess its efficacy in reduced-intensity transplants. An ongoing study presented at the 2023 American Hematology Society Annual Meeting & Expo addresses this aspect. The panel emphasizes that the combination of conditioning regimen, methotrexate, and calcineurin inhibitor contributes to toxicity, making the age of 55 years a common cutoff for ablative vs reduced-intensity transplants.

Patients with hematologic malignancies, such as acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, who have a matched donor and are eligible for myeloablative conditioning are considered for the Orca-T graft. Studies are also exploring the use of the Orca-T graft with reduced-intensity regimens and in mismatched and haploidentical donor settings, highlighting the adaptability of this platform. The addition of a defined population of Tcons promotes engraftment, even in mismatched or reduced-intensity settings.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.